Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Breast Cancer Res Treat. 2020 Apr 10;181(2):297–307. doi: 10.1007/s10549-020-05629-y

Fig. 6.

Fig. 6

Expression of the ER target gene GREB1 and the proliferation associated gene PCNA in lung metastases (a, b) or liver metastases (c, d) of host mice receiving D538G or Y537S mutant ER-containing breast cancer cells. Animals received control vehicle or K-07 orally (80 mg/kg) 6 days per week or Fulvestrant s.c. (80 mg/kg) 6 days per week, and lung and liver tissues were harvested at day 42 of treatment. RNA was prepared, and RT-PCR with human specific primers was conducted. Values are from lungs or livers of different mice in each treatment group and are mean ± SD. *, p<0.05; **, p<0.01; ***, p<0.001, ****, p<0.0001 by Student t-test for Y537S data and by Dunnett’s multiple comparisons test for D538G data.